Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: July 28, 2023 Report Code: GDHC275PIDR-7M-ST

Select Item

Dyslipidemia Market Report Overview

The Dyslipidemia market size across the 7MM was valued at $5.56 billion in 2022 and is expected to achieve a CAGR of more than 10% during 2022-2032. In 2022, the US made up the majority of total global sales. The 7MM includes the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan

Dyslipidemia Market Outlook, 2022-2032 ($ Billion)

Dyslipidemia Market Outlook, 2022-2032 ($ Billion)

Buy Full Report to Know More about The Dyslipidemia Market Forecast | Download A Free Report Sample – https://www.globaldata.com/store/talk-to-us/?report=4306032

The Dyslipidemia market research report provides a forecast model for the Dyslipidemia market through 2032 as well as an overview of the disease, including epidemiology, symptoms, diagnosis, and disease management.

Market Size (2022) $5.56 billion
CAGR (2022 – 2032) >10%
Forecast Period 2022-2032
Key Countries ·       The US

·       France

·       Germany

·       Italy

·       Spain

·       United Kingdom

·       Japan
Leading Players ·       AstraZeneca

·       Pfizer

·       Merck

·       Sanofi/Regeneron

·       Amgen

·       Novartis

·       Abbott

·       AbbVie

·       Amarin

·       Amryt Pharma

·       Esperion Therapeutics
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Dyslipidemia Market Dynamics

  • The growing global prevalence of dyslipidemia due to an increase in obesity, sedentary lifestyles, and unhealthy dietary habits is expected to drive the market in the coming years.
  • As the global population continues to age, the prevalence of dyslipidemia is likely to increase.
  • Improved awareness about the health risks associated with dyslipidemia and increased efforts in screening and diagnosis are expected to lead to more people being diagnosed with the condition.
  • The price of novel launched drugs for dyslipidemia and the restriction of access to highly-priced new therapies may hinder the potential growth in the coming years.

Dyslipidemia Market Segmentation by Countries

The US is likely to dominate the market over the forecast period owing to the large prevalence of dyslipidemia patients.

Some of the key countries in the Dyslipidemia market are the US, France, Germany, Italy, Spain, the UK, and Japan. The US had the highest share of the market in 2022 and is anticipated to continue doing so during the forecast period. This can be attributed to the growing number of pipeline drugs entering the dyslipidemia market in the US as well as the higher overall price of drugs when compared to the 5EU and Japan.

Dyslipidemia Market Analysis by Countries, 2022 (%)

Dyslipidemia Market Analysis by Countries, 2022 (%)

Buy Full Report for More Country Insights into The Dyslipidemia Market, Download A Free Report Sample

Dyslipidemia Market - Competitive Landscape

During the forecast period, GlobalData predicts that Novartis’s Leqvio will have the largest market sales of all dyslipidemia drugs.

The dyslipidemia market is highly competitive. Several companies are leaders in this space. These companies have a significant market share and offer a range of products for the management of dyslipidemia. The major players in the dyslipidemia space are AstraZeneca, Pfizer, Merck, Sanofi/Regeneron, Amgen, Novartis, Abbott, AbbVie, Amarin, Amryt Pharma, and Esperion Therapeutics.

Dyslipidemia Market Analysis by Companies, 2022

Dyslipidemia Market Analysis by Companies, 2022

Buy Full Report to Know More About Companies into The Dyslipidemia Market, Download A Free Report Sample

Segments Covered in the Report

Dyslipidemia Country Outlook (Value, $ Billion, 2022-2032)

  • The US
  • France
  • Germany
  • Italy
  • Spain
  • The UK
  • Japan

Scope

  • Overview of dyslipidemia, including epidemiology, symptoms, diagnosis, and disease management.

  • Annualized dyslipidemia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the dyslipidemia therapeutics market.

  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for dyslipidemia treatment. The most promising candidates in late-stage development are profiled.

  • Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

According to GlobalData, the drug sales in the dyslipidemia market are expected to grow significantly between 2022 and 2032, with an overall compound annual growth rate (CAGR) of 10.8%. In 2022, GlobalData estimated the total dyslipidemia market to be valued at $5.56 billion across the 7MM. In 2022, the US made up the majority of total global sales, with $4.12 billion (74%). The 5EU accounted for 21% of the global dyslipidemia market sales with an estimated value of $1.18 billion million and Japan’s dyslipidemia market sales were estimated to be $252.9 million in 2022, accounting for 5% of the market.

By the end of the forecast period in 2032, GlobalData expects the dyslipidemia market to grow at a CAGR of 10.8%, reaching sales of $15.53 billion, with the US accounting for 78% of the global market with a market value of $12.06 billion. This could be due to the large prevalence of dyslipidemia in the US, as well as the higher overall price of drugs as compared to the 5EU and Japan. Moreover, the US has more pipeline drugs entering the dyslipidemia market during the forecast period compared to the 5EU and Japan. The 5EU is anticipated to grow with a CAGR of 8.3%, reaching sales of $2.63 billion. Japan accounts for 5% of the total sales with a CAGR of 12.8% by the end of the forecast period.

Major drivers of the dyslipidemia market growth during the forecast period are –

• The increasing global prevalence of dyslipidemia due to an increase in obesity, sedentary lifestyles, and unhealthy dietary habits. As the global population continues to age, the prevalence of dyslipidemia is likely to increase.

• Improved awareness about the health risks associated with dyslipidemia and increased efforts in screening and diagnosis are expected to lead to more people being diagnosed with the condition.

• Therapies with new targets will enter the market, which will significantly boost market growth.

• The launch of the first oral PCSK9 inhibitor, Merck’s MK-0616, as well as other promising pipeline therapies, including NewAmsterdam’s oral CETP inhibitor, obicetrapib, and Akcea Therapeutics’s apoC-III, olezarsen.

Major barriers that will restrict the growth of the dyslipidemia market during the forecast period are:

• The price of novel launched drugs for dyslipidemia and the restriction of access to highly priced new therapies.

• Widespread use of cheap, generic drugs making it difficult for high-priced branded therapies to penetrate the market.

• Continued generic erosion of Pfizer’s Lipitor, AstraZeneca’s Crestor (rosuvastatin), as well as Merck’s Zetia (ezetimibe) across the 7MM.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

To know about our Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at GlobalData.

NewAmsterdam Pharma
Dicerna
BASF
Arrowhead
Akcea
Novartis
Pfizer
Sanofi/Regeneron
Amgen
Amryt
Abbott
Amarin
Esperion Therapeutics
Eli Lilly
Novo Nordisk

Table of Contents

About GlobalData 2

1 Dyslipidemia: Executive Summary 8

1.1 Dyslipidemia market will exhibit strong growth during the forecast period, reaching sales of $15.53 billion in 2032 9

1.2 Key players will continue their competitive position in the dyslipidemia market over the forecast period 10

1.3 Patient compliance, the availability of cost-effective drugs, and therapies that target lipoprotein (a) are the greatest unmet needs in the dyslipidemia space 12

1.4 Late-stage pipeline therapies are anticipated to drive growth in the dyslipidemia market 14

1.5 What do physicians think? 15

2 Introduction 18

2.1 Catalyst 18

2.2 Related reports 18

2.3 Upcoming reports 19

3 Disease Overview 20

3.1 Etiology and pathophysiology 20

3.1.1 Etiology 20

3.1.2 Pathophysiology 21

4 Epidemiology 23

4.1 Disease background 23

4.2 Risk factors and comorbidities 24

4.3 Global and historical trends 25

4.4 Forecast methodology 27

4.4.1 Sources 27

4.4.2 Forecast assumptions and methods 33

4.4.3 Forecast assumptions and methods: total prevalent cases of dyslipidemia 34

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of dyslipidemia 35

4.4.5 Forecast assumptions and methods: total prevalent cases of familial hypercholesterolemia 36

4.4.6 Forecast assumptions and methods: total prevalent cases of increased low-density lipoprotein cholesterol 37

4.4.7 Forecast assumptions and methods: total prevalent cases of high triglycerides 39

4.4.8 Forecast assumptions and methods: total prevalent cases of very high triglycerides 41

4.4.9 Forecast assumptions and methods: total prevalent cases of low high-density lipoprotein cholesterol 42

4.5 Epidemiological forecast for dyslipidemia (2022–32) 45

4.5.1 Total prevalent cases of dyslipidemia 45

4.5.2 Age-specific total prevalent cases of dyslipidemia 46

4.5.3 Sex-specific total prevalent cases of dyslipidemia 47

4.5.4 Diagnosed prevalent cases of dyslipidemia 48

4.5.5 Age-specific diagnosed prevalent cases of dyslipidemia 49

4.5.6 Sex-specific diagnosed prevalent cases of dyslipidemia 50

4.5.7 Total prevalent cases of familial hypercholesterolemia 51

4.5.8 Total prevalent cases of increased low-density lipoprotein cholesterol 52

4.5.9 Age-specific total prevalent cases of increased low-density lipoprotein cholesterol 53

4.5.10 Sex-specific total prevalent cases of increased low-density lipoprotein cholesterol 54

4.5.11 Total prevalent cases of high triglycerides 55

4.5.12 Age-specific total prevalent cases of high triglycerides 56

4.5.13 Sex-specific total prevalent cases of high triglycerides 57

4.5.14 Total prevalent cases of very high triglycerides 58

4.5.15

4.2.16 Age-specific total prevalent cases of very high triglycerides 59

4.5.16 Sex-specific total prevalent cases of very high triglycerides 60

4.5.17 Total prevalent cases of low high-density lipoprotein 61

4.5.18 Age-specific total prevalent cases of low high-density lipoprotein cholesterol 62

4.5.19 Sex-specific total prevalent cases of low high-density lipoprotein cholesterol 63

4.5.20 Total prevalent cases of mixed dyslipidemia 64

4.6 Discussion 65

4.6.1 Epidemiological forecast insight 65

4.6.2 COVID-19 impact 66

4.6.3 Limitations of the analysis 67

4.6.4 Strengths of the analysis 67

5 Disease Management 69

5.1 Diagnosis and treatment overview 69

5.1.1 Diagnosis overview 69

5.2 KOL insights on disease management 73

6 Competitive Assessment 79

6.1 Overview 79

7 Unmet Needs and Opportunity Assessment 94

7.1 Overview 94

7.2 Therapies that target lipoprotein (a) 95

7.3 Efficacious triglyceride-lowering therapies 98

7.4 Cost-effective therapies for dyslipidemia 100

7.5 Personalized treatment 102

7.6 Improving diagnosis, patient education, and long-term compliance 103

8 R&D Strategies 106

8.1 Overview 106

8.1.1 New targets and mechanisms of action 106

8.1.2 Personalized medicine 106

8.1.3 Combination therapies 107

8.1.4 Non-pharmacological interventions 107

8.2 Clinical trials design 107

8.2.1 Clinical trials endpoint selection for dyslipidemia 107

8.2.2 Compliance and adherence 108

8.2.3 Duration of trials 108

9 Pipeline Assessment 109

9.1 Overview 109

9.2 Promising drugs in clinical development 110

10 Pipeline Valuation Analysis 113

10.1 Overview 113

10.2 Competitive assessment 114

11 Current and Future Players 115

11.1 Overview 115

11.2 Deal-making trends 120

12 Market Outlook 121

12.1 Global markets 121

12.1.1 Forecast 121

12.1.2 Drivers and barriers – global issues 124

12.2 US 124

12.2.1 Forecast 124

12.2.2 Key events 126

12.2.3 Drivers and barriers 126

12.3 5EU 127

12.3.1 Forecast 127

12.3.2 Key events 129

12.3.3 Drivers and barriers 129

12.4 Japan 130

12.4.1 Forecast 130

12.4.2 Key events 132

12.4.3 Drivers and barriers 132

13 Appendix 133

13.1 Bibliography 133

13.2 Abbreviations 137

13.3 Methodology 139

13.3.1 Forecasting methodology 139

13.4 Primary research – KOLs interviewed for this report 140

13.4.1 KOLs 140

13.5 Primary research – prescriber survey 141

13.6 About the authors 142

13.6.1 Analyst 142

13.6.2 Therapy Area Director 142

13.6.3 Epidemiologist 142

13.6.4 Global Director of Therapy Analysis and Epidemiology 143

13.6.5 Global Head and EVP of Healthcare Operations and Strategy 143

Contact Us 144

Table

Table 1: Dyslipidemia: key metrics in the 7MM 8

Table 2: Fredrickson’s classification of dyslipidemia 20

Table 3: Risk factors and comorbidities for dyslipidemia 25

Table 4: Total prevalent cases of increased LDL-C, both sexes, N, ages ≥20 years, 2022–32 52

Table 5: Total prevalent cases of high TGs, both sexes, N, ages ≥20 years, 2022–32 55

Table 6: Total prevalent cases of very high TGs, both sexes, N, ages ≥20 years, 2022–32 58

Table 7: Total prevalent cases of low HDL-C, both sexes, N, ages ≥20 years, 2022–32 61

Table 8: AACE optimal/near-optimal, borderline, and high-risk serum lipid concentrations 70

Table 9: Factors considered for different CVD risk calculators 70

Table 10: Treatment guidelines for dyslipidemia 72

Table 11: Top 10 deals by value, 2018–22 120

Table 12: Dyslipidemia market – global drivers and barriers, 2022–32 124

Table 13: Key events impacting sales for dyslipidemia in the US, 2022–32 126

Table 14: Dyslipidemia market – drivers and barriers in the US, 2022–32 126

Table 15: Key events impacting sales for dyslipidemia in the 5EU, 2022–32 129

Table 16: Dyslipidemia market – drivers and barriers in the 5EU, 2022–32 129

Table 17: Key events impacting sales for dyslipidemia in Japan, 2022–32 132

Table 18: Dyslipidemia market – drivers and barriers in Japan, 2022–32 132

Table 19: High-prescribing physicians (non-KOLs) surveyed, by country 141

Figures

Figure 1: Global sales forecast by country for dyslipidemia in 2022 and 2032 10

Figure 2: Analysis of the company portfolio gap in dyslipidemia during the forecast period 12

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of dyslipidemia during the forecast period 15

Figure 4: Modern classification of dyslipidemia, and primary and secondary causes 21

Figure 5: Target of marketed and pipeline therapies 22

Figure 6: 7MM, total prevalence of dyslipidemia, men and women, %, ages ≥20 years, 2022 26

Figure 7: 7MM, diagnosed prevalence of dyslipidemia, men and women, %, ages ≥20 years, 2022 26

Figure 8: 7MM, sources used and not used to forecast the diagnosed prevalent cases of dyslipidemia 28

Figure 9: 7MM, sources used and not used to forecast the total prevalent cases of high LDL-C 29

Figure 10: 7MM, sources used and not used to forecast the total prevalent cases of high TGs and very high TGs 30

Figure 11: 7MM, sources used and not used to forecast the total prevalent cases of low HDL-C 31

Figure 12: 7MM, sources used and not used to forecast the total prevalent cases of FH 32

Figure 13: 7MM, sources used to forecast the total prevalent cases of mixed dyslipidemia 33

Figure 14: 7MM, total prevalent cases of dyslipidemia, N, both sexes, ages ≥20 years, 2022 45

Figure 15: 7MM, total prevalent cases of dyslipidemia by age, N, both sexes, 2022 46

Figure 16: 7MM, total prevalent cases of dyslipidemia by sex, N, ages ≥20 years, 2022 47

Figure 17: 7MM, diagnosed prevalent cases of dyslipidemia, N, both sexes, ages ≥20 years, 2022 48

Figure 18: 7MM, diagnosed prevalent cases of dyslipidemia by age, N, both sexes, 2022 49

Figure 19: 7MM, diagnosed prevalent cases of dyslipidemia by sex, N, ages ≥20 years, 2022 50

Figure 20: 7MM, total prevalent cases of FH, N, both sexes, ages ≥20 years, 2022 51

Figure 21: 7MM, total prevalent cases of increased LDL-C by age, N, both sexes, 2022 53

Figure 22: 7MM, total prevalent cases of increased LDL-C by sex, N, ages ≥20 years, 2022 54

Figure 23: 7MM, total prevalent cases of high TGs by age, N, both sexes, 2022 56

Figure 24: 7MM, total prevalent cases of high TGs by sex, N, ages ≥20 years, 2022 57

Figure 25: 7MM, total prevalent cases of very high TGs by age, N, both sexes, 2022 59

Figure 26: 7MM, total prevalent cases of very high TGs by sex, N, ages ≥20 years, 2022 60

Figure 27: 7MM, total prevalent cases of low HDL-C by age, N, both sexes, 2022 62

Figure 28: 7MM, total prevalent cases of low HDL-C by sex, N, ages ≥20 years, 2022 63

Figure 29: 7MM, total prevalent cases of mixed dyslipidemia, N, both sexes, ages ≥20 years, 2022 64

Figure 30: AHA/ACC and ESC/EAS guidelines 72

Figure 31: Unmet needs and opportunities in dyslipidemia 95

Figure 32: Overview of the development pipeline in dyslipidemia 110

Figure 33: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for dyslipidemia in the 7MM during the forecast period 111

Figure 34: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for dyslipidemia in the 7MM during the forecast period 112

Figure 35: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care (SOC), statins 114

Figure 36: Analysis of the company portfolio gap in dyslipidemia during the forecast period 119

Figure 37: Global (7MM) sales forecast by country for dyslipidemia in 2022 and 2032 122

Figure 38: Global (7MM) sales forecast by drug class for dyslipidemia in 2022 and 2032 123

Figure 39: Sales forecast by drug class for dyslipidemia in the US in 2022 and 2032 125

Figure 40: Sales forecast by drug class for dyslipidemia in the 5EU in 2022 and 2032 128

Figure 41: Sales forecast by drug class for dyslipidemia in Japan in 2022 and 2032 131

Frequently asked questions

Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Dyslipidemia reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 in real time.

  • Access a live Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more